Finally, we discuss the potential clinical implications of A>I(G) RNA editing; researchers are exploring ADAR1 inhibitors and targeting specific RNA-editing sites to improve cancer treatments, though challenges like off-target effects and tumor variability must be addressed, with current applications showing promise primarily in cancers other than BC. The gene discussed is ADAR; the disease is neoplasm.